TransMedics Group’s (TMDX) “Neutral” Rating Reaffirmed at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a $75.00 target price on the stock, down from their previous target price of $116.00.

A number of other research firms have also recently issued reports on TMDX. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Robert W. Baird lowered their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. TD Cowen lowered their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Finally, Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Price Performance

Shares of TMDX stock opened at $65.71 on Tuesday. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group has a 12-month low of $60.80 and a 12-month high of $177.37. The firm has a fifty day moving average of $92.92 and a 200-day moving average of $130.29. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of 69.90 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) earnings per share. On average, equities research analysts forecast that TransMedics Group will post 1 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,417 shares of company stock valued at $2,240,738 in the last 90 days. 7.00% of the stock is currently owned by insiders.

Institutional Trading of TransMedics Group

Several hedge funds and other institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the second quarter worth approximately $47,000. USA Financial Formulas bought a new stake in TransMedics Group in the 3rd quarter valued at $55,000. Quarry LP grew its holdings in TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after buying an additional 312 shares in the last quarter. National Bank of Canada FI increased its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares during the period. Finally, Signaturefd LLC lifted its holdings in shares of TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.